Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

SAB Biotherapeutics (SABSW) EBITDA (2021 - 2025)

SAB Biotherapeutics' EBITDA history spans 5 years, with the latest figure at -$15.8 million for Q4 2025.

  • For Q4 2025, EBITDA fell 57.56% year-over-year to -$15.8 million; the TTM value through Dec 2025 reached -$49.0 million, down 14.08%, while the annual FY2025 figure was $13.6 million, 139.68% up from the prior year.
  • EBITDA reached -$15.8 million in Q4 2025 per SABSW's latest filing, down from -$12.7 million in the prior quarter.
  • In the past five years, EBITDA ranged from a high of $813924.0 in Q1 2021 to a low of -$18.9 million in Q4 2023.
  • Average EBITDA over 5 years is -$8.6 million, with a median of -$7.8 million recorded in 2022.
  • Peak YoY movement for EBITDA: tumbled 924.07% in 2022, then skyrocketed 46.97% in 2024.
  • A 5-year view of EBITDA shows it stood at -$7.3 million in 2021, then decreased by 7.02% to -$7.9 million in 2022, then crashed by 140.12% to -$18.9 million in 2023, then surged by 46.97% to -$10.0 million in 2024, then plummeted by 57.56% to -$15.8 million in 2025.
  • Per Business Quant, the three most recent readings for SABSW's EBITDA are -$15.8 million (Q4 2025), -$12.7 million (Q3 2025), and -$9.7 million (Q2 2025).